The DEA’s Fentanyl Profiling Program (FPP) performs in-depth chemical analyses on fentanyl and fentanyl-related samples obtained from seizures throughout the United States. This report summarizes the findings for these analyses for Calendar Year 2021. FPP data is not intended to reflect U.S. market share, but is rather a snapshot of...

DEA Administrator Anne Milgram's statement on a potential mass fentanyl poisoning event in Gadsden County, Florida on July 2, 2022.

This case should send a clear message to any foreign leader who corruptly abuses their power to support drug cartels. If you take drug money for your election, if you accept drug cartel bribes, if you traffic deadly drugs, if you protect criminal drug cartels, if you turn the power...

The DEA is seeing a nationwide spike in fentanyl-related mass-overdose events involving three or more overdoses occurring close in time at the same location. In just the past two months, there have been at least 7 confirmed mass overdose events across the United States resulting in 58 overdoses and 29...

DEA Administrator Anne Milgram's remarks (as delivered) at a December 16, 2021 press conference announcing the results of "One Pill Can Kill" Phase Two

DEA officials report a dramatic rise in the number of fake pills containing at least 2 mg of fentanyl, which is considered a deadly dose.

DEA’s mission is to keep American communities safe and healthy and we are in the midst of an overdose crisis that has reached a devastating new height. 265 people die every day from drug overdoses. Countless more [people] overdose and are fortunate to survive. This is a national crisis. It...

What is it? Many counterfeit pills are made to look like prescription opioids – such as oxycodone (Oxycontin®, Percocet®), hydrocodone (Vicodin®), and alprazolam (Xanax®); or stimulants like amphetamines (Adderall®) – but contain fentanyl or methamphetamine. Criminal drug networks are mass-producing fake pills and falsely marketing them as legitimate prescription pills...

This document is an internal Drug Enforcement Administration quality system document. The document is updated periodically and current as of June 21, 2021 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document in their entirety...

This document is an internal Drug Enforcement Administration quality system document. The document is updated periodically and current as of March 29, 2021 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document in their entirety...